Trial Information

Summary: SWOG S0536 "A phase II trial of combination carboplatin, paclitaxel, cetuximab and bevacizumab (NSC-704865) followed by cetuximab and bevacizumab in patients with advanced non-small cell lung cancer"

The purpose of this study is to find out what effects, ggo and/or bad; carboplatin, paclitaxel, cetuximab and bevacizumab have the patient and the lung cancer. The main purpose is to learn abouth the safety of this combination.

Patient Inclusion Criteria

• Patients must have histologically or cytologically proven newly diagnosed selected Stage IIIB (T4 lesion due to malignant pleural effusion) or stage IV advanced primary non-small cell lung cancer.
• Prior radiation is permitted however at least three weeks must have elapsed since completion.
• At least four weeks must have elapsed since surgery.

Patient Exclusion Criteria

• Patients with known brain metastases are not eligible.
• Patients must not have received any prior systemic chemotherapy or biologic therapy.

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.